University of Cambridge launches vaccine race to fight all coronaviruses-world news

Cambridge University confirmed Wednesday that it plans to start testing potential new vaccines against Covid-19 as well as all future coronavirus spills from animals to humans.

The new vaccine candidate, DIOS-CoVax2, uses a bank of all known coronavirus gene sequences, including those from bats. It is believed to be the natural host for many relatives of the human coronavirus.

A vaccine that clears all trials can be delivered painlessly to the skin without a needle by a spring-loaded jet injection.

Click here for the full range of Covid-19

“Our approach includes 3D computer modeling of SARS-CoV-2. [Covid-19] Virus structure. The virus itself and its relatives-SARS, MERS, and other coronaviruses use information about coronaviruses that are threatening to “spill” on humans and threaten to cause human epidemics in the future,” says the institute. According to the director, Professor Jonathan Heaney. Virology zoologist at the University of Cambridge, founder of DIOSynVax, a Cambridge spin-out company.

“We are looking for that armored tink. This is an important part of the virus that can be used to build a vaccine that directs the immune response. Ultimately, only SARS-CoV-2 Not only that, but it also aims to create a vaccine that protects against other related coronaviruses that can spill from animals to humans,” he said.

Heeney said the team’s strategy involves targeting domains of viral structure that are absolutely critical for docking cells, while avoiding parts that could make things worse. It was

“In the end, mimicry is the synthetic part of the virus, minus the nonessential elements that can cause a bad immune response,” he added.

His team has developed a library of computer-generated antigen structures encoded by synthetic genes that can target the key regions of the virus and train the human immune system to generate beneficial antiviral responses.

These immune responses include neutralizing antibodies that block viral infection, and T cells that eliminate virally infected cells.

This so-called “laser-specific” computer-generated approach helps to avoid the deleterious inflammatory immune response that can be caused by the recognition of the wrong portion of the coronavirus surface.

“Due to the urgent need to tackle pandemics, most research groups are using established approaches to vaccine development. We all hope that current clinical trials will yield good results, Even successful vaccines can have limitations: they may not be suitable for vulnerable people, for example, I don’t know how long their effects will last.” DIOSynVax Chief Executive Officer, Rebecca Kinsley, a postdoc at the University of Cambridge.

“Our approach-providing a custom designed immunoselective vaccine antigen using synthetic DNA-is innovative and well suited for complex viruses such as coronavirus. “We will have a vaccine that is safe and can be manufactured and distributed at a low cost,” she said.

Hoping to take part in a human trial by the end of this year, DIOS-CoVax2 is the latest UK government-backed vaccine candidate to fund £1.9 million as part of a collaboration between DIOSynVax. Trial, University of Cambridge, University Hospital Southampton NHS Foundation Trust.

The team says that their proposed new vaccine can be lyophilized as a powder and is therefore heat stable, which means that it does not need to be refrigerated. This makes transportation and storage much easier, especially in low and middle income countries. It can be delivered through the PharmaJet Tropis intradermal needleless injection system, which delivers vaccines in less than 1/10th of a second jet injection.

“The NIHR Southampton Clinical Research Facility is a director,” said Professor Saul Faust. “In clinical trials, testing vaccinations through the skin of people using needleless devices is of great interest. The idea that a vast number of people in the world could be offered future vaccines. It’s a term.”

Oxford University said that a trial of a potential vaccine against Covid-19, which is being developed at AstraZeneca, could be put in front of this year’s regulators if scientists can collect enough data. Has made it clear, so the news will come out.

As is well known, the Oxford vaccine shows early promise in the first human trials that generated an immune response and is one of the leading candidates for the race to help humans to be vaccinated against the deadly novel coronavirus. I emphasized my position as.